Evaluation of Non-Invasive Tests for Metabolic Liver Disease
NCT07122700
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metabolic Associated Fatty Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Cirrhosis, Liver
- NASH
- Liver Fibrosis
- Liver Fat
- Liver Steatoses
- Liver Inflammation
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Foundation for the National Institutes of Health
- Last updated on ClinicalTrials.gov
- August 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Clinical Pharmacology of Miami · Miami, FL
Ohio · 1
- Ohio Clinical Trials · Columbus, OH
Texas · 2
- First Surgical Hospital · Bellaire, TX
- Endeavor Clinical Trials · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.